Program
BMS-986454
A development code.
Its studies are mostly in Arthritis, Rheumatoid, led by Bristol-Myers Squibb.
Furthest: phase 1, since Oct 11, 20232 company-led studies, 1 open or runningNext primary completion: Jun 28, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 21 open or running | phase 1since Oct 11, 2023 | Oct 11, 2023 | Jun 28, 2027phase 1 · NCT07171983 |
- Named in Bristol-Myers Squibb’s own pipeline as
BMS-986454
, phase 1, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06086886 · 63 enrolled · United Kingdom
- Sep 11, 2025Phase 1 study in Arthritis, RheumatoidNCT07171983 · 46 planned · India
Ahead
- Jun 28, 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT07171983
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07171983Arthritis, Rheumatoid · India | 1 | Recruiting | Jun 28, 2027 | 46 |
| NCT06086886Healthy Participants · United Kingdom | 1 | Completed | Dec 20, 2024 | 63 |
How it is read
Names in the registry
- “BMS-986454”, 2 entries
Codes read as this program: BMS986454.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.